Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease

Gut

Volumn 59, Issue 2, 2010, Pages 258-266

  Asanuma, Taketoshi ^a,b   Ono, Masafumi ^c   Kubota, Kei ^c   Hirose, Akira ^c   Hayashi, Yoshihiro ^c   Saibara, Toshiji ^c   Inanami, Osamu ^a   Ogawa, Yasuhiro ^c   Enzan, Hideaki ^c   Onishi, Saburo ^c   Kuwabara, Mikinori ^a   Oben, Jude A ^d,e  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c KOCHI MEDICAL SCHOOL   (Japan)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERUCARBOTRAN; SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL FUNCTION; CELL TRANSPORT; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL ANIMAL; FEMALE; FLUORESCENCE ANGIOGRAPHY; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; KUPFFER CELL; LIVER BIOPSY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; STEATOSIS;

ANIMALS; CELL COUNT; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; FERROSOFERRIC OXIDE; HUMANS; KUPFFER CELLS; LIVER CIRCULATION; MAGNETIC RESONANCE IMAGING; MALE; MICROCIRCULATION; PHAGOCYTOSIS; RATS; RATS, WISTAR; RATS, ZUCKER; SEVERITY OF ILLNESS INDEX;

EID: 77149180096     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.176651     Document Type: Article

References (33)

1. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999e2002. Am J Gastroenterol 2006;101:76-82.
2. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999;353:1634-6.
3. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
4. Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007;292:E740-7.
5. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009;49:989-97.
6. Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008;138:1452-5.
7. Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide- binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007;17:1374-80.
8. Gao Y, Song LX, Jiang MN, et al. Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. Inflammation 2008;31:121-32.
9. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998;12:57-65.
10. Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002;282:G1-5.
11. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
12. Fox ES, Broitman SA, Thomas P. Bacterial endotoxins and the liver. Lab Invest 1990;63:733-41.
13. Imai Y, Murakami T, Yoshida S. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000;32:205-12.
14. Ward J, Guthrie JA, Scott DJ, et al. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 2000;216:154-62.
15. Elizondo G, Weissleder R, Stark DD, et al. Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology 1990;174:797-801.
16. Kato N, Ihara S, Tsujimoto T, et al. Effect of resovist on rats with different severities of liver cirrhosis. Invest Radiol 2002;37:292-8.
17. Tanimoto A, Oshio K, Suematsu M, et al. Relaxation effects of clustered particles. J Magn Reson Imaging 2001;14:72-7.
18. Hirose A, Ono M, Saibara T, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007;45:1375-81.
19. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001;21:89-104.
20. Lawaczeck R, Bauer H, Frenzel T, et al. Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting. Pre-clinical profile of SH U555A. Acta Radiol 1997;38:584-97.
21. Asanuma T, Hirano Y, Yamamoto K, et al. MR imaging of hepatic injury in the LEC rat under a high magnetic field (7.05 T). J Vet Med Sci 1999;61:239-44.
22. Asanuma T, Ohkura K, Yamamoto T, et al. Three-dimensional magnetic resonance imaging of lung and liver tumors in mice by use of transversal multislice magnetic resonance images. Comp Med 2001;51:138-44.
23. Bhunchet E, Eishi Y, Wake K. Contribution of immune response to the hepatic fibrosis induced by porcine serum. Hepatology 1996;23:811-7.
24. Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006;239:105-12.
25. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
26. Ijaz S, Yang W, Winslet MC, et al. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003;10:447-56.
27. Farrell GC. Is bacterial ash the flash that ignites NASH? Gut 2001;48:148-9.
28. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003;38:681-7.
29. Moriyasu F, Iijima H, Tsuchiya K, et al. Diagnosis of NASH using delayed parenchymal imaging of contrast ultrasound. Hepatol Res 2005;33:97-9.
30. Li Z, Lin H, Yang S, et al. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 2002;123:1304-10.
31. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997;94:2557-62.
32. Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003;38:1188-98.
33. Otogawa K, Kinoshita K, Fujii H, et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J pathol 2007;170:967-80.